A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma

A neoadjuvant immunotherapy platform clinical trial allows for rapid evaluation of treatment-related changes in tumors and identifying targets to optimize treatment responses. We enrolled patients with resectable pancreatic adenocarcinoma into such a platform trial (NCT02451982) to receive pancreati...

Descripción completa

Detalles Bibliográficos
Autores principales: Heumann, Thatcher, Judkins, Carol, Li, Keyu, Lim, Su Jin, Hoare, Jessica, Parkinson, Rose, Cao, Haihui, Zhang, Tengyi, Gai, Jessica, Celiker, Betul, Zhu, Qingfeng, McPhaul, Thomas, Durham, Jennifer, Purtell, Katrina, Klein, Rachel, Laheru, Daniel, De Jesus-Acosta, Ana, Le, Dung T., Narang, Amol, Anders, Robert, Burkhart, Richard, Burns, William, Soares, Kevin, Wolfgang, Christopher, Thompson, Elizabeth, Jaffee, Elizabeth, Wang, Hao, He, Jin, Zheng, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281953/
https://www.ncbi.nlm.nih.gov/pubmed/37339979
http://dx.doi.org/10.1038/s41467-023-39196-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281953/
https://www.ncbi.nlm.nih.gov/pubmed/37339979
http://dx.doi.org/10.1038/s41467-023-39196-9

Ejemplares similares